# Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke -2

Study · id `cardio:ct-nct07263776` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07263776](<https://clinicaltrials.gov/study/NCT07263776>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07263776

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 692 participants.

## Technical summary

Registry record NCT07263776. Randomized; quadruple masking; primary purpose treatment. Start 2025-12-05 (actual); primary completion 2026-09-18 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 692 participants (enrolled count; ClinicalTrials.gov record NCT07263776, source copy `cardio:ctgov-nct07263776-2026-10-06`, retrieved 2026-10-26)
- Started: 2025-12-05 (actual) (ClinicalTrials.gov record NCT07263776, source copy `cardio:ctgov-nct07263776-2026-10-06`, retrieved 2026-10-26)
- Primary completion: 2026-09-18 (actual) (ClinicalTrials.gov record NCT07263776, source copy `cardio:ctgov-nct07263776-2026-10-06`, retrieved 2026-10-26)
- Completion: 2027-06-11 (anticipated) (ClinicalTrials.gov record NCT07263776, source copy `cardio:ctgov-nct07263776-2026-10-06`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07263776, source copy `cardio:ctgov-nct07263776-2026-10-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07263776-2026-10-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke -2
- Acronym: IRIS-2
- Condition: Acute Ischemic Stroke
- Intervention (Drug): Tocilizumab
- Intervention (Drug): Placebo
- Lead sponsor: Capital Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Capital Medical University (`cardio:org-capital-medical-university`)

## Provenance

Content hash: 137d1b48d921486403aa2587926b1f726119fa7632c0033d823814339c086406
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
